Atlas FDA

Thoraflex™ Hybrid

FDA premarket approval P210006/S016 · decided 2026-01-29

Approval details

PMA number
P210006
Supplement
S016
Supplement type
Special (Immediate Track)
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
Thoraflex™ Hybrid
Generic name
Hybrid stent graft, thoracic aortic lesion treatment
Applicant
Vascutek, Ltd.
Date received
2025-12-30
Decision date
2026-01-29
Days to decision
30 days
Decision code
APPR
Product code
QSK
Advisory committee
Cardiovascular
Expedited review
No
Location
Inchinnan
Statement
an update to the lFU to include additional language regarding early imaging surveillance for patients at risk for intraluminal thrombosis

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Gelweave™ Vascular Prostheses (K241550)Vascutek, Ltd.2025-02-27
Gelsoft™ Plus Vascular Prostheses (K241070)Vascutek, Ltd.2024-11-15
Vascutek Gelsoft Plus ERS Vascular Graft (K202703)Vascutek, Ltd.2021-04-06
Vascutek Gelseal Patch, Vascutek Gelsoft Patch, Vascutek Thin Wall Carotid Patch (K200955)Vascutek, Ltd.2020-07-08
Gelseal Vascular Grafts, Gelsoft Vascular Grafts, Gelsoft Plus Vascular Grafts (K162803)Vascutek, Ltd.2017-07-14
Gelweave Vascular Grafts (K162794)Vascutek, Ltd.2017-06-30
GELWEAVE BRANCHED VASCULAR GRAFTS WITH RADIOPAQUE MARKERS (K093817)Vascutek, Ltd.2010-01-07
MAXIFLO, TAPERFLO (K092863)Vascutek, Ltd.2009-10-08